Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 21, 2016; 22(27): 6287-6295
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6287
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6287
Table 1 Clinical characteristics of patients
| Number of patients (n = 20) | |
| Sex | |
| Male | 11/20 |
| Female | 9/20 |
| Age | |
| mean | 64.2 |
| range | 28-80 |
| Number of metastatic sites | |
| 1-2 | 7/20 |
| ≥ 3 | 13/20 |
| Tumor differentiation | |
| G1-G2 | 12/20 |
| G3 | 8/20 |
| Associated chemotherapy | |
| Folfox4 | 6/20 |
| Bi-weekly XELOX | 14/20 |
| Line of therapy | |
| First | 17/20 |
| Second | 3/20 |
| Response to treatment | |
| PR | 6/20 |
| SD | 9/20 |
| PD | 5/20 |
| Median number of cycles | 9 (range: 5-14) |
- Citation: Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295
- URL: https://www.wjgnet.com/1007-9327/full/v22/i27/6287.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i27.6287